Cortisol Augmentation of Prolonged Exposure Therapy
| Status: | Completed |
|---|---|
| Conditions: | Psychiatric |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 10/14/2017 |
| Start Date: | July 2008 |
| End Date: | February 2011 |
This study seeks to examine the efficacy of hydrocortisone administration in the augmentation
of the therapeutic effects of Prolonged Exposure (PE) therapy, an empirically tested
treatment shown to be effective in the the treatment of posttraumatic stress disorder (PTSD).
The augmentation builds on both the translation of neuroscience findings demonstrating the
effects of glucocorticoids (GCs) on learning, and on empirical clinical findings from other
investigators demonstrating beneficial effects of GCs in reducing traumatic memories in
trauma-exposed persons.
of the therapeutic effects of Prolonged Exposure (PE) therapy, an empirically tested
treatment shown to be effective in the the treatment of posttraumatic stress disorder (PTSD).
The augmentation builds on both the translation of neuroscience findings demonstrating the
effects of glucocorticoids (GCs) on learning, and on empirical clinical findings from other
investigators demonstrating beneficial effects of GCs in reducing traumatic memories in
trauma-exposed persons.
Inclusion Criteria:
- Veterans who experienced a criterion A trauma while deployed, and a current diagnosis
of PTSD with a minimum of 6 months
- Capable of understanding, reading and writing English
Exclusion Criteria:
- Incapable and/or unwilling to provide written informed consent prior to participation
- Unwilling and/or unable to discontinue current psychotherapy
- Regular use of psychotropic medication including antidepressants, benzodiazepines,
lithium, mood stabilizers, over-the-counter supplements (melatonin, kava-kava,
ephedra)
- Regular use of oral or inhaled steroids
- Significant illness (e.g., type I or II diabetes requiring the use of insulin, HIV,
AIDS, seizure disorder, anemia, Lyme disease, etc.)
- The veteran, the veteran's physician, or the study physician think that the veteran's
clinical state necessitates the prompt initiation of pharmacotherapy or other
treatment that would preclude involvement in the study
- Morbid obesity (VMI > 40)
- Clinically significant laboratory abnormalities as determine during medical clearance
procedures
- For women, a positive pregnancy test
- Heavy smoking (more than 2 packs a day)
- Substance and/or alcohol abuse and/or dependence within the previous 6 months
- Response of 3 or 4 on the suicidality items of the HDRS or an assessed serious suicide
risk
- Current psychosocial problems that might interfere with treatment compliance
- A lifetime history of schizophrenia, schizoaffective disorder, bipolar disorder,
obsessive compulsive disorder or PTSD due to a trauma not sustained in the combat
theater
We found this trial at
1
site
Click here to add this to my saved trials
